BR0309603A - Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação - Google Patents

Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação

Info

Publication number
BR0309603A
BR0309603A BR0309603-3A BR0309603A BR0309603A BR 0309603 A BR0309603 A BR 0309603A BR 0309603 A BR0309603 A BR 0309603A BR 0309603 A BR0309603 A BR 0309603A
Authority
BR
Brazil
Prior art keywords
hpv
pharmaceutical composition
preparation process
polypeptide
mutated
Prior art date
Application number
BR0309603-3A
Other languages
English (en)
Inventor
Sophie Hallez
Ars Ne Burny
Alain Jacquet
Alex Bollen
Original Assignee
Univ Bruxelles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0205173A external-priority patent/FR2839072A1/fr
Priority claimed from FR0304170A external-priority patent/FR2839080B1/fr
Application filed by Univ Bruxelles filed Critical Univ Bruxelles
Publication of BR0309603A publication Critical patent/BR0309603A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"POLIPEPTìDEO E7 MUTADO DE HPV-16, COMPOSIçãO FARMACêUTICA QUE O COMPREENDE E SEU PROCESSO DE PREPARAçãO". A presente invenção refere-se a um polipeptídeo E7 mutado obtido a partir do Papilomavírus humano HPV-16 assim como à composição farmacêutica que o compreende e ao seu processo de preparação.
BR0309603-3A 2002-04-24 2003-04-24 Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação BR0309603A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0205173A FR2839072A1 (fr) 2002-04-24 2002-04-24 Produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, composition immunogene contenant ledit produit d'expression et son procede de preparation
US41046102P 2002-09-13 2002-09-13
FR0304170A FR2839080B1 (fr) 2003-04-03 2003-04-03 Procede de preparation d'un produit d'expression d'un adn codant une proteine e7 mutee de hpv-16, par des cellules de la levure pichia pastoris
PCT/BE2003/000073 WO2003090664A2 (en) 2002-04-24 2003-04-24 Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process

Publications (1)

Publication Number Publication Date
BR0309603A true BR0309603A (pt) 2005-02-15

Family

ID=29273339

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309603-3A BR0309603A (pt) 2002-04-24 2003-04-24 Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação

Country Status (6)

Country Link
US (1) US20060099219A1 (pt)
EP (1) EP1515987A2 (pt)
AU (1) AU2003221650A1 (pt)
BR (1) BR0309603A (pt)
CA (1) CA2483468A1 (pt)
WO (1) WO2003090664A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100063048A (ko) * 2007-07-31 2010-06-10 더 존스 홉킨스 유니버시티 신생물성 또는 감염성 장애의 면역예방 또는 면역치료를 위한 폴리펩티드-핵산 접합체

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806350A (en) * 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6235523B1 (en) * 1998-09-04 2001-05-22 Connaught Laboratories Limited Vectors for DNA immunization against cervical cancer
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.

Also Published As

Publication number Publication date
WO2003090664A2 (en) 2003-11-06
EP1515987A2 (en) 2005-03-23
AU2003221650A8 (en) 2003-11-10
CA2483468A1 (en) 2003-11-06
AU2003221650A1 (en) 2003-11-10
WO2003090664A3 (en) 2004-01-29
US20060099219A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
ECSP045300A (es) Antígenos virales
BRPI0414492A8 (pt) solvato acetônico do dimetóxi docetaxel e seu processo de preparação
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
SE0001899D0 (sv) New compounds
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
DE602006012665D1 (de) Kristalline formen von 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-ä4-((r)-tetrahydrofuran-3-yloxy)-benzylü-benzol, zubereitungsverfahren dafür und dessen verwendung zur arzneimittelherstellung
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
NO20055741D0 (no) Nye kjemiske forbindelser
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
DE60206272D1 (de) Chelatorkonjugate mit verbesserten eigenschaften
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
DE502004008819D1 (de) Medikament zur wachstumsinhibierung von tumoren
BRPI0412803A (pt) alfa-fetoproteìna humana não-glicosilada, métodos de produção e usos dos mesmos
UA107177C2 (uk) Імуногенна композиція цвс2 та спосіб приготування такої композиції
WO2009148229A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
BR0309603A (pt) Polipeptìdeo e7 mutado de hpv-16, composição farmacêutica que o compreende e seu processo de preparação
WO2009148230A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
DE60305279D1 (de) Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
DE60224280D1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
WO2007014497A8 (en) A composition comprising silver nanoparticles and the use thereof
BR0308201A (pt) Derivados de quinolina
EA200700191A1 (ru) Композиции, содержащие никорандил, способ получения и применение
ATE267600T1 (de) Mikroemulsionen zur transdermalen verabreichung von apomorphin für die behandlung von morbus parkinson

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2051 DE 27/04/2010.